Clozapine functions through the prefrontal cortex serotonin 1A receptor to heighten neuronal activity via calmodulin kinase II-NMDA receptor interactions

Journal of Neurochemistry

Volumn 120, Issue 3, 2012, Pages 396-407

  Purkayastha, Sudarshana ^a   Ford, Jason ^a   Kanjilal, Baishali ^a   Diallo, Souleymane ^a   Del Rosario Inigo, Joseph ^a   Neuwirth, Lorenz ^a   El Idrissi, Abdeslem ^a   Ahmed, Zaghloul ^a   Wieraszko, Andrzej ^a   Azmitia, Efrain C ^b   Banerjee, Probal ^a  

^a CITY UNIVERSITY OF NEW YORK   (United States)

^b NEW YORK UNIVERSITY   (United States)

Author keywords

5 HT1A receptor; clozapine; prefrontal cortex; schizophrenia; signal transduction

Indexed keywords

2 AMINO 5 PHOSPHONOVALERIC ACID; AMPA RECEPTOR; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CLOZAPINE; METHYL BETA CYCLODEXTRIN; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; PHOSPHOLIPASE C BETA; SEROTONIN 1A RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN ELECTROPHYSIOLOGY; BRAIN SLICE; CONTROLLED STUDY; DRUG EFFECT; EXCITATORY POSTSYNAPTIC POTENTIAL; IMMUNOBLOTTING; IMMUNOPRECIPITATION; MALE; MOUSE; NERVE FIBER; NONHUMAN; POSTSYNAPTIC DENSITY; POSTSYNAPTIC MEMBRANE; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PYRAMIDAL NERVE CELL; SPIKE;

ACTION POTENTIALS; ANIMALS; ANIMALS, NEWBORN; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 2; CLOZAPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ELECTRIC STIMULATION; ENZYME INHIBITORS; EXCITATORY AMINO ACID AGENTS; GENE EXPRESSION REGULATION; IMMUNOPRECIPITATION; MALE; MICE; NEURONS; PREFRONTAL CORTEX; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTORS, N-METHYL-D-ASPARTATE; SEROTONIN AGENTS; SIGNAL TRANSDUCTION;

EID: 84855716018     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2011.07565.x     Document Type: Article

References (54)

1. Andersen W. W., and, Collingridge G. L., (2001) The LTP program: a data acquisition program for on-line analysis of long-term potentiation and other synaptic events. J. Neurosci. Methods 108, 71-83. (Pubitemid 32664044)
2. Anthony T. W., and, Azmitia E. C., (1997) Molecular characterization of antipeptide antibodies against the 5-HT1A receptor: evidence for state-dependent antibody binding. Mol. Brain Res. 50, 277-284. (Pubitemid 27488916)
3. Arvanov V. L., Liang X., Schwartz J., Grossman S., and, Wang R. Y., (1997) Clozapine and haloperidol modulate N-methyl-d-aspartate- and non-N-methyl-d-aspartate receptor-mediated neurotransmission in rat prefrontal cortical neurons in vitro. J. Pharmacol. Exp. Ther. 283, 226-234. (Pubitemid 27438966)
4. 2A and alpha1b-adrenergic receptors entirely mediate dopamine release, locomotor response and behavioural sensitization to opiates and psychostimulants. Eur. J. Neurosci. 20, 3073-3084. (Pubitemid 40007302)
5. Bantick R. A., Deakin J. F., and, Grasby P. M., (2001) The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics? J. Psychopharmacol. 15, 37-46. (Pubitemid 32242102)
6. Bernstein H. G., Krause S., Krell D., Dobrowolny H., Wolter M., Stauch R., Ranft K., Danos P., Jirikowski G. F., and, Bogerts B., (2007) Strongly Reduced Number of Parvalbumin-Immunoreactive Projection Neurons in the Mammillary Bodies in Schizophrenia. Ann. N Y Acad. Sci. 1096, 120-127. (Pubitemid 47092505)
7. Broderick P. A., and, Piercey M. F., (1998) Clozapine, haloperidol, and the D4 antagonist PNU-101387G: in vivo effects on mesocortical, mesolimbic, and nigrostriatal dopamine and serotonin release. J. Neural Transm. 105, 749-767. (Pubitemid 28454524)
8. 2/calmodulin-dependent kinase II in prefrontal cortical pyramidal neurons. J. Neurosci. 39, 36553-36562.
9. Chemel B. R., Roth B. L., Armbruster B., Watts V. J., and, Nichols D. E., (2006) WAY-100635 is a potent dopamine D4 receptor agonist. Psychopharmacology (Berl.) 188, 244-251. (Pubitemid 44371162)
10. Chen L., and, Yang C. R., (2002) Interaction of dopamine D1 and NMDA receptors mediates acute clozapine potentiation of glutamate EPSPs in rat prefrontal cortex. J. Neurophysiol. 87, 2324-2336. (Pubitemid 34670705)
11. Csernansky J. G., and, Bardgett M. E., (1998) Limbic-cortical neuronal damage and the pathophysiology of schizophrenia. Schizophr. Bull. 24, 231-248. (Pubitemid 28404983)
12. Darmani N. A., (1998) The silent and selective 5-HT1A antagonist, WAY 100635, produces via an indirect mechanism, a 5-HT2A receptor-mediated bhaviour in mice during the day but not at night. J. Neural Transm. 105, 635-643. (Pubitemid 28454516)
13. Deighan C., Woollhead A. M., Coston J. F., and, McGrath J. C., (2004) Hepatocytes from α1B-adrenoceptor knockout mice reveal compensatory adrenoceptor subtype substitution. Br. J. Pharmacol. 142, 1031-1037. (Pubitemid 39037053)
14. Diaz-Mataix L., Scorza M. C., Bortolozzi A., Toth M., Celada P., and, Artigas F., (2005) Involvement of 5-HT1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action. J. Neurosci. 25, 10831-10843. (Pubitemid 41692613)
15. Duncan G. E., Zorn S., and, Lieberman J. A., (1999) Mechanisms of typical and atypical antipsychotic drug action in relation to dopamine and NMDA receptor hypofunction hypotheses of schizophrenia. Mol. Psychiatry 4, 418-428. (Pubitemid 29497729)
16. Fink C. C., and, Meyer T., (2002) Molecular mechanisms of CaMKII activation in neuronal plasticity. Curr. Opin. Neurobiol. 12, 293-299. (Pubitemid 34615755)
17. Fletcher A., Cliffe I. A., and, Dourish C. T., (1993) Silent 5-HT1A receptor antagonists: utility as research tools and therapeutic agents. Trends Pharmacol. Sci. 14, 441-448.
18. Forster E. A., Cliffe I. A., Bill D. J., Dover G. M., Jones D., Reilly Y., and, Fletcher A., (1995) A pharmacological profile of the selective silent 5-HT1A receptor antagonist, WAY-100635. Eur. J. Pharmacol. 281, 81-88.
19. Gao M., Liu C. L., Yang S., Jin G. Z., Bunney B. S., and, Shi W. X., (2007) Functional coupling between the prefrontal cortex and dopamine neurons in the ventral tegmental area. J. Neurosci. 27, 5414-5421. (Pubitemid 46790172)
20. Glavin G. B., (1995) The antisecretory effects of clozapine, a dopamine D4 receptor antagonist, are blocked by the dopamine D1 receptor antagonist, SCH23390. Life Sci. 56, PL365-PL368.
21. Gonzalez-Maeso J., A R. L., Yuen T., et al. (2008) Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature 452, 93-97. (Pubitemid 351355090)
22. Ichikawa J., Ishii H., Bonaccorso S., Fowler W. L., O'Laughlin I. A., and, Meltzer H. Y., (2001) 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J. Neurochem. 76, 1521-1531. (Pubitemid 32198256)
23. Kim J. S., Kornhuber H. H., Schmid-Burgk W., and, Holzmüller B., (1980) Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypotesis on schophrenia. Neurosci. Lett. 20, 379-382. (Pubitemid 11160082)
24. Kobe F. R. U., Woehlera A., Wlodarczyk J., Papusheva E., Bao G., Zeug A., Richter D.W., Neher E., and, Ponimaskin E., (2008) Stimulation- and palmitoylation-dependent changes in oligomeric conformation of serotonin 5-HT1A receptors. Biochim. Biophys. Acta Mol. Cell Res. 1783, 1503-1516.
25. Leveque J. C., Macia W., Rajadhyaksha A., et al. (2000) Intracellular modulation of NMDA receptor function by antipsychotic drugs. J. Neurosci. 20, 4011-4020. (Pubitemid 30365671)
26. Lipina T., Labrie V., Weiner I., and, Roder J., (2005) Modulators of the glycine site on NMDA receptors, D-serine and ALX 5407, display similar beneficial effects to clozapine in mouse models of schizophrenia. Psychopharmacology 179, 54-67. (Pubitemid 40576692)
27. Lisman J. E., and, McIntyre C. C., (2001) Synaptic plasticity: a molecular memory switch. Curr. Biol. 11, R788-R791. (Pubitemid 32931006)
28. Martel J. C., Leduc N., Ormiere A. M., Faucillon V., Danty N., Culie C., Cussac D., and, Newman-Tancredi A., (2007) WAY-100635 has high selectivity for serotonin 5-HT(1A) versus dopamine D(4) receptors. Eur. J. Pharmacol. 574, 15-19. (Pubitemid 47503165)
29. Marti M., Mela F., Bianchi C., Beani L, and, Morari M., (2002) Striatal dopamine-NMDA receptor interactions in the modulation of glutamate release in the substantia nigra pars reticulata in vivo: opposite role for D1 and D2 receptors. J. Neurochem. 83, 635-644. (Pubitemid 35231817)
30. Mehta M., Ahmed Z., Fernando S. S., Cano Sanchez P., Adayev T., Ziemnicka D., Wieraszko A., and, Banerjee P., (2007) Plasticity of 5-HT1A receptor-mediated signaling during early postnatal brain development. J. Neurochem. 101, 918-928. (Pubitemid 46683871)
31. Millan M. J., (2000) Improving the Treatment of Schizophrenia: focus on Serotonin (5-HT)1A Receptors. J. Pharmacol. Exp. Ther. 295, 853-861.
32. Paulus M. P., Frank L., Brown G. G., and, Braff D. L., (2003) Schizophrenia subjects show intact success-related neural activation but impaired uncertainty processing during decision-making. Neuropsychopharmacology 28, 795-806.
33. Paxinos G., and, Franklin K. B. J., (2004) The Mouse Brain in Stereotaxic Coordinates. 2nd ed, Elsevier Academic Press, Amsterdam; Boston.
34. Pei L., Lee F. J. S., Moszczynska A., Vukusic B., and, Liu F., (2004) Regulation of dopamine D1 receptor function by physical interaction with the NMDA receptors. J. Neurosci. 24, 1149-1158. (Pubitemid 38177022)
35. Pilowsky L. S., Bressan R.A., Stone J. M., Erlandsson K., Mulligan R. S., Krystal J. H., and, Ell P.J., (2006) First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients. Mol. Psychiatry 11, 118-119. (Pubitemid 43164609)
36. Remington G., (2003) Understanding antipsychotic "atypicality": a clinical and pharmacological moving target. J. Psychiatry Neurosci. 28, 275-284. (Pubitemid 37153435)
37. Renner U., Glebov K., Lang T., Papusheva E., Balakrishnan S., Keller B., Richter D. W., Jahn R., and, Ponimaskin E., (2007) Localization of the mouse 5-hydroxytryptamine1A receptor in lipid microdomains depends on its palmitoylation and is involved in receptor-mediated signaling. Mol. Pharmacol. 72, 502-513. (Pubitemid 47347285)
38. Rollema H., Lu Y., Schmidt A. W., and, Zorn S. H., (1997) Clozapine increase dopamine release in prefrontal cortex by 5-HT1A receptor activation. Eur. J. Pharmacol. 338, R3-R5. (Pubitemid 27507749)
39. Roth B. L., Sheffler D., and, Potkin S. G., (2003) Atypical antipsychotic drug actions: unitary or multiple mechanisms for 'atypicality'? Clin. Neurosci. Res. 3, 108-117. (Pubitemid 36975299)
40. Salvatore M. F., Garcia-Espana A., Gldstein M., Deutch A. Y., and, Haycock J. W., (2000) Stoichiometry of tyrosine hydroxylase phosphorylation in the nigrostriatal and mesolimbic systems in vivo: effects of acute haloperidol and related compounds. J. Neurochem. 75, 225-232. (Pubitemid 30418187)
41. Schiller J., Schiller Y., and, Clapham D. E., (1998) NMDA receptors amplify calcium influx into dendritic spines during associative pre- and postsynaptic activation. Nat. Neurosci. 1, 114-118.
42. Schmitt A., Zink M., Müller B., May B., Herv Jatzko A., Braus D. F., and, Henn F. A., (2003) Effects of long-term antipsychotic treatment on NMDA receptor binding and gene expression of subunits. Neurochem. Res. 28, 235-241. (Pubitemid 36207348)
43. Schwieler L., Engberg G., and, Erhardt S., (2004) Clozapine modulates midbrain dopamine neuron firing via interaction with the NMDA receptor complex. Synapse 52, 114-122. (Pubitemid 38429039)
44. Scott L., and, Aperia A., (2009) Interaction between N-methyl-d-aspartic acid receptors and D1 dopamine receptors: an important mechanism for brain plasticity. Neuroscience 158, 62-66.
45. Semyanov A., and, Godukhin O., (2001) Epileptiform activity and EPSP-spike potentiation induced in rat hippocampal CA1 slices by repeated high-K+: involvement of ionotropic glutamate receptors and Ca2+/calmodulin- dependent protein kinase II. Neuropharmacology 40, 203-211.
46. Shenton M. E., Dickey C. C., Frumin M., and, McCarley R. W., (2001) A review of MRI findings in schizophrenia. Schizophr. Res. 49, 1-52. (Pubitemid 32451739)
47. Strack S., and, Colbran R. J., (1998) Autophosphorylation-dependent targeting of calcium/calmodulin-dependent protein kinase II by the NR2B subunit of the N-methyl-d-aspartate receptor. J. Biol. Chem. 273, 20689-20692. (Pubitemid 28385342)
48. Takano A., Suhara T., Kusumi I., et al. (2006) Time course of dopamine D2 receptor occupancy by clozapine with medium and high plasma concentrations. Prog. Neuropsychopharmacol. Biol. Psychiatry 30, 75-81. (Pubitemid 43021324)
49. Tseng K. Y., Lewis B. L., Hashimoto T., Sesack S. R., Kloc M., Lewis D. A., and, O'Donnell P., (2008) A neonatal ventral hippocampal lesion causes functional deficits in adult prefrontal cortical interneurons. J. Neurosci. 28, 12691-12699.
50. Wang X., Zhong P., and, Yan Z., (2002) Dopamine D4 receptors modulate GABAergic signaling in pyramidal neurons of prefrontal cortex. J. Neurosci. 22, 9185-9193. (Pubitemid 35356161)
51. Wieraszko A., (2004) Amplification of evoked potentials recorded from mouse hippocampal slices by very low repetition rate pulsed magnetic fields. Bioelectromagnetics 25, 537-544. (Pubitemid 39421854)
52. Wittmann M., Marino M. J., Henze D. A., Seabrook G. R., and, Conn P. J., (2005) Clozapine potentiation of N-methyl-d-aspartate receptor currents in the nucleus accumbens: role of NR2B and protein kinase A/Src kinases. J. Pharmacol. Exp. Ther. 313, 594-603. (Pubitemid 40604159)
53. Yamasaki N., Maekawa M., Kobayashi K., et al. (2008) Alpha-CaMKII deficiency causes immature dentate gyrus, a novel candidate endophenotype of psychiatric disorders. Mol. Brain 1, 6.
54. 1A receptors regulate NMDA receptor channels through a microtubule-dependent mechanism. J. Neurosci. 25, 5488-5501. (Pubitemid 40800641)